Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer

Research output: Contribution to journalReview articlepeer-review

Abstract

Hormone therapies targeting androgen receptor signaling are the mainstay of treatment for patients with advanced prostate cancer. The length of clinical remission induced by hormone therapies varies substantially among treated patients. Why some patients progress rapidly after treatment while others benefit with prolonged remission is a question that remains unsolved. The androgen receptor signaling pathway is the key molecular determinant of castration resistance, and a key target for prostate cancer drug design. Recent advances in characterizing molecular processes leading to the development of castration-resistant prostate cancer, including the discovery of multiple androgen receptor splicing variants, offer opportunities for rational development of new clinical tools or approaches to predict, monitor or control/prevent prostate cancer progression in the castrate setting.

Original languageEnglish (US)
Pages (from-to)753-764
Number of pages12
JournalExpert Review of Endocrinology and Metabolism
Volume5
Issue number5
DOIs
StatePublished - Sep 2010
Externally publishedYes

Keywords

  • AR
  • AR signaling
  • AR splicing variants
  • CRPC
  • androgen receptor
  • castration-resistant prostate cancer
  • hormone therapy
  • prostate cancer

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Fingerprint Dive into the research topics of 'Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer'. Together they form a unique fingerprint.

Cite this